ValueQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMSelling/general/admin expenses2.87 M2.68 M1.64 M4.39 M2.16 M10.87 MResearch & development——————영업 이익-13.33 M4.82 M-5.88 M-8.61 M-7.34 M-17.02 MNon-Operating Income, Total0—————Interest expense, net of interest capitalized——————Non-Operating Income, excl. Interest Expenses0—————Unusual income/expense——————Pretax income-19.81 M4.82 M-5.88 M-8.61 M-250.64 M-260.31 MEquity in earnings0—————Taxes-87 K03 000003 000Non-controlling/minority interest——————After tax other income/expense0—————Net income before discontinued operations-19.73 M-54.15 M-26.64 M-146.34 M-23.5 M-250.64 MDiscontinued operations0———0—Net income-19.73 M-54.15 M-26.64 M-146.34 M-23.5 M-250.64 MDilution adjustment——————Preferred dividends——————Diluted net income available to common stockholders-19.73 M-54.15 M-26.64 M-325.34 M-23.5 M-429.64 MBasic earnings per share (Basic EPS)-0.05-0.18-0.09-1.06-0.04-1.37Diluted earnings per share (Diluted EPS)-0.05-0.18-0.09-1.06-0.04-1.37Average basic shares outstanding267.73 M293.88 M296.43 M307.17 M312.98 M1.21 BDiluted shares outstanding267.73 M293.88 M296.43 M307.17 M312.98 M1.21 BEBITDA-12.67 M—————EBIT-13.33 M—————Cost of revenue——————Other cost of goods sold——————Depreciation & amortization (cash flow)661 K629 K630 K803 K1.14 M3.2 M
Precigen Inc
Precigen, Inc. is an American biotechnology company. Its president and CEO is Helen Sabzevari.
Intrexon was founded in 1998, and is headquartered in Germantown, Maryland. With a suite of proprietary and complementary technologies, Intrexon applies engineering to biological systems to enable DNA-based control over the function and output of living cells.